Omega Diagnostics is expected to move into profit next year.
In the first half of this year, the allergy division increased its revenues by one-quarter, while the infectious disease division revenues fell by one-third. Food intolerance generates the majority of revenues and this division increased its revenues by 6% to £4.46m. Total group revenues from continuing operations were £5.23m.
VISITECT CD4 is expected to generate £500,000 in revenues this year and £2m in the year to March 2021. This provides the upside for the group.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.